Q-omics provides the consensus-scored EPHB3 profile across patient tissues and cancer cell-line models. EPHB3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, EPHB3 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, EPHB3 RNA expression shows 18,258 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where EPHB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPHB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPHB3 survival associations across molecular data types. EPHB3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPHB3 RNA expression–survival associations across cancer types. High EPHB3 expression shows unfavorable associations in BLCA, ACC and KICH, but favorable associations in STAD, UCS and GBM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for EPHB3 RNA expression.
This table summarizes EPHB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for EPHB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPHB3 shows lower tumor expression in KIRP and KICH and higher tumor expression in THCA, COAD, LUAD and LUSC. The THCA box plot shows higher EPHB3 RNA expression in tumor versus normal tissue (log2 FC = +3.705, t-test p < 0.001).
This table shows molecular features associated with EPHB3 in patient tissues and cancer cell lines. In patient samples, EPHB3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, EPHB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LUNG_NSCLC_LUAD.
